GAMMA Investing’s Autolus Therapeutics AUTL Stock Holding History

GAMMA Investing’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$31.9K	Buy	16,425 +926	+6%	+$1.77K	﹤0.01%	2655
2026 Q2	$24.8K	Buy	15,499 +8,309	+116%	+$13K	﹤0.01%	2724
2026 Q1	$9.92K	Sell	7,190 -2,995	-29%	-$4.55K	﹤0.01%	3073
2025 Q4	$20.3K	Buy	10,185 +774	+8%	+$1.19K	﹤0.01%	2610
2025 Q3	$15.3K	Sell	9,411 -634	-6%	-$1.24K	﹤0.01%	2658
2025 Q2	$22.9K	Buy	10,045 +3,188	+46%	+$5.27K	﹤0.01%	2385
2025 Q1	$10.6K	Buy	6,857 +2,327	+51%	+$4.72K	﹤0.01%	2717
2024 Q4	$10.6K	Buy	4,530 +1,670	+58%	+$5.64K	﹤0.01%	2580
2024 Q3	$10.4K	Buy	2,860 +1,391	+95%	+$5.55K	﹤0.01%	2442
2024 Q2	$5.11K	Buy	1,469 +411	+39%	+$1.77K	﹤0.01%	2565
2024 Q1	$6.75K	Buy	1,058 +751	+245%	+$4.68K	﹤0.01%	2259
2023 Q4	$1.85K	Buy	+307	New	+$1.17K	﹤0.01%	2601

Other funds holding AUTL

BAM

Byrne Asset Management Kingston, New Jersey $179M AUM 29.67% 1-Year Est. Return

GAMMA Investing's AUTL Position: Q3 2026 in Review

GAMMA Investing increased its Autolus Therapeutics (AUTL) stake by 6% in Q3 2026, buying an estimated $1.77K and bringing the position to 16,425 shares worth $31.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2655.

GAMMA Investing first reported a position in AUTL in Q4 2023 and has held it in 12 quarters since. 2 funds tracked by Wall St. Rank hold AUTL as of Q3 2026.

GAMMA Investing held 16,425 shares of Autolus Therapeutics worth $31.9K as of Q3 2026.
GAMMA Investing bought 926 Autolus Therapeutics shares in Q3 2026, an estimated $1.77K.
Autolus Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #2655 holding.
GAMMA Investing first reported a position in Autolus Therapeutics in Q4 2023 and has held it in 12 quarters since.
2 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.